University Of Colorado Denver

  • Image

    Colorado Clinical and Translational Sciences Institute (CCTSI)

    Catalyze and enhance scientific discovery, innovation, dissemination and translation across the lifespan; Educate and sustain a resilient, innovative and diverse translational science workforce; Promote and ensure an efficient, safe, collaborative and integrated research environment; Engage stakeholders and communities across the entire translational spectrum

    In short, our mission is to support, connect and train our CTR teams.
  • University Of Colorado Denver
    Background: The University of Colorado Anschutz Medical Campus (CU-Anschutz) is a complex research environment comprised of three hospitals and multiple University research entities, including Colorado Clinical and Translational Sciences Institute (CCTSI; CTSA. CU-AMC has over $600M in research grants and over 4,000 clinical research protocols and trials. COVID-19 suspended almost all clinical
  • As the country rides a new wave of the COVID-19 pandemic, it faces a riptide that’s threatening its course. The delta variant, the now-predominant strain of coronavirus, prompted President Joe Biden’s call for booster shots for all vaccinated adults on Aug. 18 and underscored discussions at a research summit that ran parallel to the president’s nationwide address. “This is, of course, something

  • image of a board game with medical imagery
    -
    University Of Colorado Denver
    Nov 4, 2021 | 12:00 PM - 03:00 pm MT The theme of this year's HYBRID conference is COVID-19 Research in the News: What Ethical Issues Does This Raise? KEYNOTE PRESENTER: Timothy Caulfield, Research Director of the Health Law Institute at the University of Alberta. FLASH TALKS: Michelle Barron, MD COVID-19 Hindsite is 2020: Masks & Personal Stories Senior Director of Infection Prevention and
  • In March of 2020, the pandemic drove Coloradans to enter lockdown mode. This was no different for researchers on the CU Anschutz Medical Campus. The result was that research operations were completely shuttered unless they were related to COVID-19 or essential to patient care. A group of researchers from across the country wanted to learn how different institutions handled closing research down

  • Findings from a new study published in the New England Journal of Medicine underscore the importance of early, intensive treatment for youth-onset type 2 diabetes. Phil Zeitler, MD, PhD, has been treating youth with type 2 diabetes for more than 20 years. He and a team of researchers published a paper today on the TODAY2 study in the New England Journal of Medicine on the long-term complications

  • The CCTSI responded to the pandemic by issuing a rapid-release RFA to address COVID-19. CCTSI leaders called it the COVID-19-Rapid Research Pilot Program. They released the RFA on Monday evening, March 30 and closed the application process just four days later. This new pilot grant program supported the development of novel diagnostic and treatment methods and innovative technologies related to

  • Adit Ginde, MD, and the Colorado Clinical Translational Sciences Institute team are spreading the word about monoclonal antibody treatment for COVID-19. As the COVID-19 pandemic continues to lurk in many communities, aided by vaccine hesitancy and the emergence of disease mutations like the Delta variant, physicians are still looking for effective ways to treat those who test positive for the

  • In vaccine clinical trials, the Pfizer and Moderna COVID-19 vaccines were shown to be about 95% effective in preventing COVID-19. Now a study from the Centers for Disease Control and Prevention uses real-world data to show that indeed, those who are 65 years and older who are fully vaccinated are 94% percent less likely to be hospitalized for COVID-19 than those who have not been vaccinated

  • Dr. James Feinstein, a pediatrician who has dedicated his career to treating children with complex chronic conditions and severe neurological impairments, has developed a tool so parents may easily and comprehensively report their child’s symptoms. He has just published his research on this topic in JAMA Pediatrics and in JAMA Open.

  • The nation has been coping with the pandemic for more than a year, and in this time, researchers have learned a great deal about how to treat COVID-19. Yet they have also been faced with what they still must learn, including how to reach the individuals who have been most dramatically impacted by the disease and who could benefit the most from new treatments. A new $8.7 million grant from the

  • Virtual International Conference
    -
    University Of Colorado Denver

    The Adult and Child Consortium for Health Outcomes Research and Delivery Science (ACCORDS), along with the Colorado Clinical and Translational Sciences Institute (CCTSI) at the University of Colorado Anschutz Medical Campus, is proud to welcome you to the second international Colorado Pragmatic Research in Health Conference (COPRH Con). Designed for junior faculty (K awards, career development

  • University Of Colorado Denver

    The COVIDome Project at the University of Colorado Anschutz Medical Campus is a collaborative multidisciplinary project, led by Joaquin Espinosa, PhD, that aims to accelerate translational research in COVID19 by generating and integrating matched multi-omics and clinical datasets and making them broadly accessible through an online portal ahead of publication.

  • Urea Cycle Disorders Consortium

    Urea cycle disorders (UCDs) are rare but devastating genetic conditions. In 2003, the Urea Cycle Disorders Consortium (UCDC) became one of the first members of the RDCRN. Since then, UCDC has flourished into an international network of 16 academic centers in the United States, Canada and Europe that provide state-of-the-art care and conduct cutting-edge clinical research. The UCDC is currently

  • Phenylalanine Families and Researchers Exploring Evidence (PHEFREE)

    The Phenylalanine Families and Researchers Exploring Evidence (PHEFREE) Consortium studies the health, neurologic, cognitive, neuropsychiatric, patient-reported and quality-of-life outcomes in individuals with chronic elevations of the amino acid phenylalanine in blood (hyperphenylalaninemia). In the United States, elevated blood phenylalanine is typically detected at birth through newborn

  • North American Mitochondrial Disease Consortium (NAMDC)

    Mitochondrial diseases affect approximately 1 in every 5,000 people. These diseases can cause muscle weakness, difficulty thinking, seizures, hearing and vision loss, digestive problems, learning disabilities, and organ failure. The North American Mitochondrial Disease Consortium (NAMDC) is a network of clinicians and researchers at 17 different clinical sites working to better understand

  • Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)

    Leukodystrophies are a complex, often progressive group of disorders affecting the white matter of the brain due to the loss or absence of myelin, the lipid membrane that insulates axons in the central nervous system. Despite advances in the diagnosis of these disorders, they remain widely under-recognized, with unmet gaps in clinical care and curative therapeutics. The Global Leukodystrophy

  • Genetic Disorders of Mucociliary Clearance Consortium (GDMCC)

    The Genetic Disorders of Mucociliary Clearance Consortium (GDMCC) focuses on several inherited and acquired disorders that cause thickened, infected secretions to accumulate in the upper and lower airways. Its work is conducted at eight clinical research sites across the United States and Canada. During the past 15 years, the consortium has made numerous advances that profoundly changed clinical

  • Frontiers in Congenital Disorders of Glycosylation (FCDGC)

    Congenital disorders of glycosylation (CDG) consist of more than 130 different inborn errors of metabolism at an estimated overall incidence of greater than 1 in 100,000. While these disorders were first genetically defined in the 1990s, there is no data available on their natural history, no comprehensive patient registry, no reliable screening tests for many types, and large gaps in clinical

  • Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

    Eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic colitis are disorders in which a type of immune cell (called eosinophils) builds up in the digestive tract, causing gastrointestinal tissue damage. These disorders are painful, lifelong, and make it hard or impossible for people to eat many or all foods. The Consortium of Eosinophilic Gastrointestinal

  • Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium (CPIC)

    The Congenital and Perinatal Infections Consortium (CPIC) is focused on reducing the morbidity and mortality of rare viral infections such as congenital cytomegalovirus (CMV) disease, neonatal herpes simplex virus (HSV) infection, and neonatal viral sepsis caused by enteroviruses (EVs) and the related human parechoviruses (HPeVs). These infections have been grouped together because of their

  • Brain Vascular Malformation Consortium (BVMC)

    The Brain Vascular Malformation Consortium (BVMC) focuses on three rare brain conditions: familial cerebral cavernous malformation (CCM), Sturge-Weber syndrome (SWS), and hereditary hemorrhagic telangiectasia (HHT). These disorders are poorly understood, costly to manage, and can cause serious complications such as hemorrhages, seizures, and problems with spinal cord, nerve or brain function. Over

  • FDA approves a drug that dramatically reduces seizure frequency Most physicians who conduct clinical trials say they were drawn to research because they wanted to discover new treatments and cures. Such findings are rare, but, every once in a while, clinical trials result in a new treatment that is life changing. This was the case with two trials led by pediatric neurologist Kelly Knupp, MD, who

  • University Of Colorado Denver
    When the SARS-CoV-2 pandemic reached Colorado in early March 2020, the leadership team of the Colorado Clinical and Translational Sciences Institute (CCTSI) rapidly responded to this public health emergency by establishing a new rapid-review pilot grant program, the CCTSI COVID-19-Related Research Pilot Program (C2R2 Pilot) with $100,000 budgeted for this program. The goal of the C2R2 Pilot
  • Converge Logo
    -
    University Of Colorado Denver
    What is emotionally challenging research? How does recognizing your emotions during research lead to more ethical and methodologically sound practices? If you are interested in learning more, please join us for this brief 30-minute webinar. During this session, the presenters will provide an overview of the newly released CONVERGE Conducting Emotionally Challenging Research Training Module. The
  • University Of Colorado Denver

    Leaders from the CCTSI have developed a new course offering to enhance research career success: Researcher Management & Leadership Training is a massive open online course on the global learning platform Coursera. This course is targeted to early career researchers and mentors who believe that modern scientific careers require management skills and want to be research leaders—especially current

  • CU Anschutz and CCTSI play a key role in developing antiviral medications and working to attenuate the inflammatory response. In just a few months, physicians have developed key findings through multiple clinical trials at CU Anschutz, testing previously FDA-approved drugs and new medications to battle COVID-19. “Two months ago I would not have guessed we’d have encouraging results so quickly,”

  • Few would describe the pace of academic medical research as swift. Yet last month, the CCTSI disrupted its own processes and timelines by issuing a new rapid-release RFA to address COVID-19. The CCTSI COVID-19-Related Research Pilot Program – or C2R2 – supports the development of novel diagnostic and treatment methods and innovative technologies related to the COVID-19 outbreak.

  • Banner image for the ACT Network COVID-19 webinar May 5, 2020
    -
    University Of Colorado Denver

    The Accrual to Clinical Trials (ACT) Network is an NIH/NCATS funded clinical informatics platform allowing users to query de-identified EHR data across the CTSA consortium. Using proven ACT technology and existing governance/data use agreements, the network has quickly mobilized to create a scalable COVID-19 research platform. This effort has focused on COVID-19 extensions to the ACT query

  • When Betsy McFarland, MD began her infectious disease fellowship at Children’s Hospital Colorado in 1992, she treated children in the hospital who were living with HIV. The experience was pivotal. “You see a child that is suffering, and you think ‘what can we do better?’” says Dr. McFarland. “To be able to participate in research that will make that child’s life better or some other child’s life